Session 1

THIS INITIATIVE IS BEING SUPPORTED BY A SPONSORSHIP FROM PFIZER
Disclosures & Acknowledgements

The Immunization Action Coalition has been responsible for all aspects of content development for the enclosed presentation and all other assets supporting the Take a Stand™ program. Any questions should be directed to the Immunization Action Coalition.

Pfizer is supporting this initiative because it provides focus on the importance of adult immunization. Pfizer has had no role in the creation of content for this presentation or other assets supporting the Take a Stand™ program workshops and therefore accepts no responsibility for the content.

Dr. Hsu: has received honorariums from Sanofi-Pasteur as part of Speaker’s Bureau

Acknowledgements: LJ Tan, Chief Strategy Officer IAC
Session 1
Why Adult Immunization Matters

Vincent Hsu, MD MPH FACP
Hospital Epidemiologist
Assistant Director, Internal Medicine Residency
Florida Hospital, Orlando FL

April 12, 2016
Orlando FL
Outline

• Review the burden of adult vaccine-preventable diseases in the United States

• Review adult vaccination coverage in the United States

• Discuss the changing environment for adult immunization
What is the Burden of Adult Vaccine-Preventable Diseases?
Ten Great Public Health Achievements—United States, 1900-99

1. Vaccination
2. Motor-vehicle safety
3. Safer workplaces
4. Control of infectious diseases
5. Decline in deaths from coronary heart disease and stroke
6. Safer and healthier foods
7. Healthier mothers and babies
8. Family planning
9. Fluoridation of drinking water
10. Recognition of tobacco use as a health hazard

CDC. MMWR 48(12):241-243
# Vaccine Impact in the U.S.

<table>
<thead>
<tr>
<th>Disease</th>
<th>Baseline 20th century annual morbidity</th>
<th>1998 morbidity</th>
<th>% decrease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smallpox</td>
<td>48,164</td>
<td>0</td>
<td>100%</td>
</tr>
<tr>
<td>Diptheria</td>
<td>175,885</td>
<td>1</td>
<td>100%</td>
</tr>
<tr>
<td>Pertussis</td>
<td>174,271</td>
<td>6,279</td>
<td>95.7%</td>
</tr>
<tr>
<td>Tetanus</td>
<td>1,314</td>
<td>34</td>
<td>97.4%</td>
</tr>
<tr>
<td>Polio (paralytic)</td>
<td>16,316</td>
<td>0</td>
<td>100%</td>
</tr>
<tr>
<td>Measles</td>
<td>503,282</td>
<td>89</td>
<td>99.9%</td>
</tr>
<tr>
<td>Mumps</td>
<td>152,209</td>
<td>606</td>
<td>99.6%</td>
</tr>
<tr>
<td>Rubella</td>
<td>47,745</td>
<td>345</td>
<td>99.3%</td>
</tr>
<tr>
<td>H. Influenzae type b</td>
<td>20,000</td>
<td>54</td>
<td>99.7%</td>
</tr>
</tbody>
</table>

CDC. MMWR 48(12):243-248
Burden of Vaccine-preventable Disease Among U.S. Adults

- **Influenza**
  - 3,000 to 49,000 total influenza-related deaths per year\(^1\)
  - 80%–90% of deaths among adults 65 years and older\(^2\)

- **Invasive pneumococcal disease (IPD)\(^3\)**
  - 33,900 total cases/ 3,700 total deaths in 2013
  - 91% of IPD and nearly all IPD deaths among adults

- **Pertussis in 2014\(^4\)**
  - ~24,000 cases
  - >5,000 among adults 20 years of age and older

- **Hepatitis B\(^5\)**
  - 3,050 acute cases reported in 2013
  - ~19,800 estimated

- **Zoster\(^6\)**
  - ~1 million cases of zoster annually U.S.

---

\(^1\) MMWR. 2010;59(33): 1057-1062.
\(^2\) http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0066312
\(^3\) www.cdc.gov/abcs/reports-findings/survreports/spneu13.pdf
\(^5\) www.cdc.gov/hepatitis/statistics/2013surveillance/commentary.htm#hepatitisB
Burden of Other Diseases Among U.S. Adults

- Ebola: 4 cases
- Avian Influenza: None
- E. coli H7:O157 from eating at Chipotle: <100 cases
- Zika virus: 107 cases (travel-associated as of 2/24)
VPDs Among U.S. Adults

**Influenza**

- 3,000–49,000 deaths per year
- 80%–90% of deaths occur in adults ≥65 years of age

CDC. MMWR. 2010;59:1057 (data from 1976-2007)


Influenza Costs Lives and Money

- Direct medical costs in U.S.: $10.4 billion
- Add in loss of work and life: $87 billion
- Vaccination (41% in 2013–14) prevented:
  - 7 million+ illnesses
  - 3 million+ medically-attended illnesses
  - 90,000+ hospitalizations

Estimated Human and Economic Burden Caused by 4 Major Adult VPDs in 2013, U.S.
(includes only adults > 65 years of age)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Cases</th>
<th>Cost (x $1,000,000)</th>
<th></th>
<th></th>
<th></th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Medical</td>
<td>Indirect</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza</td>
<td>4,019,759</td>
<td>7,503</td>
<td>810</td>
<td></td>
<td></td>
<td>8,313</td>
</tr>
<tr>
<td>Pneumococcal disease</td>
<td>440,187</td>
<td>3,572</td>
<td>215</td>
<td></td>
<td></td>
<td>3,787</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>555,989</td>
<td>1,309</td>
<td>1,709</td>
<td></td>
<td></td>
<td>3,017</td>
</tr>
<tr>
<td>Pertussis</td>
<td>207,241</td>
<td>90</td>
<td>123</td>
<td></td>
<td></td>
<td>213</td>
</tr>
<tr>
<td>Total</td>
<td>5,223,176</td>
<td>$12,474</td>
<td>$2,856</td>
<td></td>
<td></td>
<td>$15,330</td>
</tr>
</tbody>
</table>
# Recommended Adult Vaccines

## Recommended Adult Immunization Schedule—United States - 2016

Note: These recommendations must be read with the footnotes that follow containing number of doses, intervals between doses, and other important information.

### Figure 1. Recommended immunization schedule for adults aged 19 years or older, by vaccine and age group

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>AGE GROUP</th>
<th>19-21 years</th>
<th>22-26 years</th>
<th>27-49 years</th>
<th>50-59 years</th>
<th>60-64 years</th>
<th>≥ 65 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>1 dose annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, pertussis (Tdap)^1</td>
<td></td>
<td>Substitute Tdap for Td once, then Td booster every 10 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV) Female</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV) Male</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoster</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)^2</td>
<td>1 or 2 doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal 13-valent conjugate (PCV13)^3,4</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal 23-valent polysaccharide (PPSV23)^5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A^6</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis B^7^8</td>
<td>3 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal 4-valent conjugate (MenACWY) or polysaccharide (MPSV4)^1,7</td>
<td>1 or more doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B (MenB)^9</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)^10,12</td>
<td>1 or 3 doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Covered by the Vaccine Injury Compensation Program

---

Report all clinically significant postvaccination reactions to the Vaccine Adverse Event Reporting System (VAERS). Reporting forms and instructions on filing a VAERS report are available at [www.vaers.hhs.gov](http://www.vaers.hhs.gov) or by telephone. 800-822-7967.

Information on how to file a Vaccine Injury Compensation Program claim is available at [www.hrsa.gov/vaccinecompensation](http://www.hrsa.gov/vaccinecompensation) or by telephone, 800-338-2382. To file a claim for vaccine injury, contact the U.S. Court of Federal Claims, 717 Madison Place, N.W., Washington, D.C. 20005; telephone, 202-357-6400.

Additional information about the vaccines in this schedule, extent of available data, and contraindications for vaccination is also available at [www.cdc.gov/vaccines](http://www.cdc.gov/vaccines) or from the CDC-INFO Contact Center at 800-CDC-INFO (800-232-4636) in English and Spanish, 8:00 a.m. - 8:00 p.m. Eastern Time, Monday - Friday, excluding holidays.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

The recommendations in this schedule were approved by the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP); the American Academy of Family Physicians (AAFP); the America College of Physicians (ACP); the American College of Obstetricians and Gynecologists (ACOG); and the American College of Nurse-Midwives (ACNM).

[www.cdc.gov/vaccines/schedules/hcp/adult.html](http://www.cdc.gov/vaccines/schedules/hcp/adult.html)
Recommended Adult Vaccines (cont.)

**Figure 2. Vaccines that might be indicated for adults aged 19 years or older based on medical and other indications**

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>INDICATION</th>
<th>Pregnancy</th>
<th>Immuno-compromising conditions (excluding HIV infection)</th>
<th>HIV Infection CD4+ count (cells/µl)</th>
<th>Men who have sex with men (NSM)</th>
<th>Kidney failure, end-stage renal disease, on hemodialysis</th>
<th>Heart disease, chronic lung disease, chronic alcoholism</th>
<th>Apnea and persistent complement component deficiencies</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Healthcare personnel</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza*</td>
<td>3 annually</td>
<td>Contraindicated</td>
<td>1 dose Tdap during each pregnancy</td>
<td>Substitutes Tdap for Td once, then Td booster every 10 yrs</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
</tr>
<tr>
<td>Tetanus, diphtheria, pertussis (Td/Tdap)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
</tr>
<tr>
<td>Varicella*</td>
<td>4-6</td>
<td>Contraindicated</td>
<td>1 dose Tdap during each pregnancy</td>
<td></td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
</tr>
<tr>
<td>Human papillomavirus (HPV) Female</td>
<td>6-13</td>
<td>Contraindicated</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Human papillomavirus (HPV) Male</td>
<td>9-13</td>
<td>Contraindicated</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Zoster</td>
<td>6-9</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1 dose</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1 or 2 doses depending on indication</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
</tr>
<tr>
<td>Pneumococcal 13-valent conjugate (PCV13)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1, 2, or 3 doses depending on indication</td>
<td>1 dose</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1, 2, or 3 doses depending on indication</td>
<td>1 dose</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Hepatitis A*</td>
<td>4-6</td>
<td>Contraindicated</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Hepatitis B*</td>
<td>3-6</td>
<td>Contraindicated</td>
<td></td>
<td>3 doses</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Meningococcal 4 valent conjugate (MenACWY) or polysaccharide (MPSV)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1 or more doses depending on indication</td>
<td>1 dose</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Meningococcal B (MenB)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>1 or more doses depending on indication</td>
<td>1 dose</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
<tr>
<td>Neisseria meningitidis type b (Hib)*</td>
<td>Contraindicated</td>
<td></td>
<td></td>
<td>2 or 3 doses depending on vaccine</td>
<td>1 dose</td>
<td>3 doses through age 26 yrs</td>
<td>1 dose</td>
<td>2 doses</td>
<td>3 doses through age 21 yrs</td>
<td>1 dose</td>
<td>1 dose</td>
</tr>
</tbody>
</table>

*Covered by the Vaccine Injury Compensation Program

**Recommended for all persons who meet the age requirement, lack documentation of vaccination, or lack evidence of past infection; zoster vaccine is recommended regardless of past episode of zoster

**Recommended for persons with a risk factor (medical, occupational, lifestyle, or other indication)

**No recommendation

**Contraindicated

These schedules indicate the recommended age groups and medical indications for which administration of currently licensed vaccines is commonly recommended for adults aged ≥19 years, as of February 2016. For all vaccines being recommended on the Adult Immunization Schedule, a vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Licensed combination vaccines may be used whenever any components of the combination are indicated and when the vaccine's other components are not contraindicated. For detailed recommendations on all vaccines, including those used primarily for travelers or that are issued during the year, consult the manufacturers' package inserts and the complete statements from the Advisory Committee on Immunization Practices (www.cdc.gov/vaccines/hcp/acip-recs/information.html). Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

www.cdc.gov/vaccines/schedules/hcp/adult.html
How Effective is Vaccination?
Influenza vaccine effectiveness depends on:

- How you decide if someone has influenza
- What population you study—most vaccines work less well in the very young and very old
- What you mean by effective:
  - Prevents death
  - Prevents hospitalization
  - Prevents a visit to the doctor or emergency room
  - Prevents any symptoms
Effectiveness

**Influenza vaccine**

Medically-attended disease with good vaccine match

CDC. MMWR 2013;62(RR-7):1

http://www.mynycdoctor.com/tests-for-influenza-a-b/
Effectiveness

**PCV13**

Bonten. NEJM 2015;372:1114
PCV13, vaccine-type infection
www.wisegeek.net/what-is-pneumococcal-pneumonia.htm
Rates of invasive pneumococcal disease among children aged <5 years (A) and adults aged ≥65 years (B), by serotype and year. The 7-valent pneumococcal conjugate vaccine (PCV7) includes serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. All other serotypes (including 19A) were considered nonvaccine serotypes.

Effectiveness

Zoster vaccine

Oxman. NEJM 2005;352:2271

PHN, post-herpetic neuralgia
Pregnant Women

Two-for-one vaccination!

www.porticostory.org/content/BLOG/BLOG.asp
## Pertussis “Hot Spots”, 1998

<table>
<thead>
<tr>
<th>School district</th>
<th>Exemption rate (%)</th>
<th>Pertussis rate/100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lake Washington</td>
<td>1.8</td>
<td>18.2</td>
</tr>
<tr>
<td>Federal Way</td>
<td>2.2</td>
<td>26.8</td>
</tr>
<tr>
<td>Bellevue</td>
<td>3.3</td>
<td>15.7</td>
</tr>
<tr>
<td>North Shore</td>
<td>3.8</td>
<td>22.5</td>
</tr>
<tr>
<td>Vashon Island</td>
<td>8.4</td>
<td>138.3</td>
</tr>
<tr>
<td>King County</td>
<td>3.0</td>
<td>12.3</td>
</tr>
</tbody>
</table>

Data: K Reitberg, Public Health Seattle & King County
How well are we doing in vaccinating our adult population?
Adult Immunization Coverage Rates, National Health Interview Surveys, 2011–2014

- Tetanus past 10y, age ≥65
- Tetanus past 10y, age 19-49
- Pneumococcal, age ≥65
- Pneumococcal, age 19-64 at high risk
- Zoster, age ≥60

 Percent

2014 2013 2012 2011

Healthy People 2020 target

Adults with Diabetes Who Received ≥3 Doses Hepatitis B Vaccine by Age, National Health Interview Surveys, 2011–2014

<table>
<thead>
<tr>
<th>Age Group</th>
<th>2011</th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-59 yrs</td>
<td>26.9</td>
<td>28.6</td>
<td>26.3</td>
<td>23.5</td>
</tr>
<tr>
<td>≥60 yrs</td>
<td>12.4</td>
<td>13.9</td>
<td>15.1</td>
<td>13.5</td>
</tr>
</tbody>
</table>

Percent

Most Adult Immunization Rates Still Low

- HPV (≥1 dose), Women 19-26 yrs
- HPV (≥1 dose), Men 19-26 yrs
- Tdap, HCP 19-64 yrs
- Hep B ≥3 doses, HCP ≥19 yrs

2014 2013 2012

Percent

# Influenza Vaccination Coverage Among U.S. Adults, Past Four Seasons*

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Persons ≥ 18 yrs</td>
<td>38.8</td>
<td>41.5</td>
<td>42.4</td>
<td>43.6</td>
</tr>
<tr>
<td>Persons 18-49 yrs, all</td>
<td>28.6</td>
<td>31.1</td>
<td>32.3</td>
<td>33.5</td>
</tr>
<tr>
<td>Persons 18-49 yrs, high risk</td>
<td>36.8</td>
<td>39.8</td>
<td>38.7</td>
<td>39.3</td>
</tr>
<tr>
<td>Persons 50-64 yrs</td>
<td>42.7</td>
<td>45.1</td>
<td>45.3</td>
<td>47.0</td>
</tr>
<tr>
<td>Persons ≥ 65 yrs</td>
<td>64.9</td>
<td>66.2</td>
<td>65.0</td>
<td>66.7</td>
</tr>
</tbody>
</table>

* Flu vaccination coverage estimates from the BRFSS survey were calculated using Kaplan-Meier survival analysis to determine the cumulative flu vaccination coverage (≥1 dose) July 2014 through May 2015 using monthly interview data collected September 2014 through June 2015. Only BRFSS data were used to estimate coverage for adults ≥18 years.

www.cdc.gov/flu/fluuvaxview/index.htm
Ramifications of Failure to Vaccinate Adults...

• Beyond the impact to the health of the public, our ineffectiveness in immunizing adults:
  - Creates disincentive for manufacturers to enter the market
  - Leaves the chronically ill vulnerable
  - Creates disparities in access to care
    o Absence of commitment exacerbates existing barriers to immunization for those in the lower socio-economic strata and for racial and ethnic minorities
What factors lead to low adult immunization coverage?

- Patient Factors
- System Factors
- Office Factors
Factors Associated with Low Vaccination Among Adults

• **Patient factors**
  – May not have regular health care provider or only see specialists
  – Inconvenient access, competing social and economic demands
  – Many adults 18–64 years of age still unaware of ACA vaccination coverage, and many still remain uninsured

• **Provider factors**
  – Many other health issues compete with preventive services
  – Lack of provider recommendation
  – Lack of effective reminders to offer vaccinations

• **System factors**
  – Fewer requirements for vaccination (e.g., by employers)
  – State regulations differ on who can vaccinate and what vaccines are allowed (e.g., pharmacists, visiting nurse associations)

• **Complex adult vaccine schedule**
The Cow-Pock — or — the Wonderful Effects of the New Inoculation!

Vide... the Publications of the Anti-Vaccine Society.
Risk Perception Does Not Mirror Actual Risk

<table>
<thead>
<tr>
<th>What We’re Afraid Of</th>
<th>What The Real Risk Is</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shark attacks (28)</td>
<td>Dog bites (4.5 million)</td>
</tr>
<tr>
<td>Murder (14,180)</td>
<td>Suicide (33,289)</td>
</tr>
<tr>
<td>Death by peanut allergy (50)</td>
<td>Death by poisoning (27,531)</td>
</tr>
<tr>
<td>Death by plane crash (321)</td>
<td>Death by car crash (34,017)</td>
</tr>
</tbody>
</table>

Kalb. Newsweek. 2010;155(22)
Vaccinations and the Media

- Easy to scare
- Entertain
- Ultimately: Ratings

- Stories & Anecdotes
- “David vs Goliath”
- Unsung Maverick
Some Adult Immunization Facts

• **Challenges**
  - Vaccine coverage among adults is unacceptably low
  - Limited patient awareness about need for vaccines among adults
  - Adult vaccinations less integrated into clinical practice

• **Opportunities**
  - Most patients willing to get vaccinated when recommended by medical providers
  - Primary care providers believe that immunizations are an important part of the services they provide to patients
  - Systematic offering (e.g., through standing orders) and recommendations from clinicians result in higher uptake
### US Community Services Task Force: Healthcare Provider- or System-Based Strategies

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Status of Task Force Review</th>
</tr>
</thead>
<tbody>
<tr>
<td>Provider reminder systems when used alone</td>
<td>Recommended (Strong evidence)</td>
</tr>
<tr>
<td>Provider assessment and feedback</td>
<td>Recommended (Strong evidence)</td>
</tr>
<tr>
<td>Standing orders</td>
<td>Recommended (Strong evidence)</td>
</tr>
<tr>
<td>Provider education when used alone</td>
<td>Insufficient evidence</td>
</tr>
<tr>
<td>Health care-based interventions when implemented in combination</td>
<td>Recommended (Strong evidence)</td>
</tr>
</tbody>
</table>

www.thecommunityguide.org/vaccines/universally/index.html
Office Factors (examples)

• Other health issues compete with preventive services
• Practice culture (“Vaccines are for kids!”)
• Hours are inconvenient for working adults
• Lack of effective vaccination prompts to providers
• Lack of provider recommendation to patients
How can my office vaccinate more adults?
# Meta-Analysis of Interventions to Increase Use of Adult Immunization

## Table

<table>
<thead>
<tr>
<th>Intervention</th>
<th>Odds Ratio*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organizational change (e.g., standing orders, separate clinics devoted to prevention)</td>
<td>16.0</td>
</tr>
<tr>
<td>Provider reminder</td>
<td>3.8</td>
</tr>
<tr>
<td>Provider education</td>
<td>3.2</td>
</tr>
<tr>
<td>Patient financial incentive</td>
<td>3.4</td>
</tr>
<tr>
<td>Patient reminder</td>
<td>2.5</td>
</tr>
<tr>
<td>Patient education</td>
<td>1.3</td>
</tr>
</tbody>
</table>

*Compared to usual care or control group, adjusted for all remaining interventions

New Standards for Adult Immunization Practice*

• Stresses that all providers, including those who don’t provide vaccine services, have a role in ensuring patients are up to date on vaccines

• Acknowledges that:
  – Adult patients may see many different health care providers, some of whom do not stock some or all vaccines
  – Adults may get vaccinated in a medical home, at work, or retail setting

• Aim is to avoid missed opportunities and keep adult patients protected from vaccine-preventable diseases

* www.izsummitpartners.org/adult-immunization-standards
New Standards for Adult Immunization Practice (cont.)

• Calls to action for health care professionals
  – **Assess** immunization status of all patients in every clinical encounter.
  – **Strongly recommend** vaccines that patients need.
  – **Administer** needed vaccines **or refer** to a provider who can immunize.
  – **Document** vaccines given to patients, including entering them into immunization registries when available.

www.publichealthreports.org/issueopen.cfm?articleID=3145
Conclusions

• Substantial burden of disease in adults for which vaccines are available

• Vaccination rates low among adults in U.S.

• New *Standards for Adult Immunization Practice* emphasize the importance of assessing need for vaccines and providing vaccinations
Conclusions (cont.)

• U.S. Community Services Task Force highlights the use of systems-based interventions to improve immunization rates, including the implementation of standing orders.

• Many tools and resources available to:
  – Educate patients on the importance of vaccination
  – *Take A Stand™*: first of its kind national initiative to assist practices to implement vaccination standing orders.
Resources

• Take A Stand™
  – www.standingorders.org

• Read IAC publications
  – www.immunize.org/publications

• Visit IAC websites
  – www.immunize.org
  – www.vaccineinformation.org
  – www.izsummitpartners.org

• Stay ahead of the game!
  Subscribe to IAC weekly updates
  – www.immunize.org/subscribe
THANK YOU!